Ergomed (AIM:ERGO) - Cours de l'action, nouvelles et analyse

ERGO Aperçu des actions

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. Plus de détails

ERGO analyse fondamentale
Score flocon de neige
Évaluation	0/6
Croissance future	3/6
Performances passées	3/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Les bénéfices devraient augmenter 14.17% par an

Les bénéfices ont augmenté de 12.3% au cours de l'année écoulée

Analyse des risques

Volatilité du cours de l'action au cours des 3 derniers mois

Les actionnaires ont été dilués au cours de l'année écoulée

Ergomed plc Concurrents

hVIVO

AIM:HVO

UK£172.8m

C4X Discovery Holdings

AIM:C4XD

UK£30.3m

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£195.7m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Ergomed
Historique des cours de bourse
Prix actuel de l'action	UK£13.46
Plus haut sur 52 semaines	UK£13.80
Plus bas sur 52 semaines	UK£8.95
Bêta	0.79
1Variation sur 1 mois	0.90%
Variation sur 3 mois	21.26%
Variation sur 1 an	3.54%
3Variation sur 3 ans	67.41%
Variation sur 5 ans	812.54%
Évolution depuis l'introduction en bourse	728.31%

Nouvelles et mises à jour récentes

Recent updates

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

Feb 22

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Jan 18

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

Dec 13

We Think Ergomed's (LON:ERGO) Statutory Profit Might Understate Its Earnings Potential

Nov 23

Rendement pour les actionnaires

	ERGO	GB Life Sciences	GB Marché
7D	0.1%	-1.3%	-0.4%
1Y	3.5%	-29.6%	5.6%

Rendement vs Industrie: ERGO a dépassé le secteur UK Life Sciences qui a rapporté -29.6 % au cours de l'année écoulée.

Rendement vs marché: ERGO a dépassé le marché UK qui a rapporté 5.6 % au cours de l'année écoulée.

Volatilité des prix

Is ERGO's price volatile compared to industry and market?
ERGO volatility
ERGO Average Weekly Movement	8.1%
Life Sciences Industry Average Movement	4.9%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Cours de l'action stable: Le cours de l'action de ERGO a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de ERGO ( 8% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de UK.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1997	1,400	n/a	www.ergomedplc.com

Ergomed plc Résumé des fondamentaux

Comment les bénéfices et les revenus de Ergomed se comparent-ils à sa capitalisation boursière ?
ERGO statistiques fondamentales
Capitalisation boursière	UK£701.05m
Bénéfices(TTM)	UK£15.00m
Recettes(TTM)	UK£152.09m

46.7x

Ratio P/E

4.6x

Ratio P/S

Le site ERGO est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
ERGO compte de résultat (TTM)
Recettes	UK£152.09m
Coût des recettes	UK£68.82m
Marge brute	UK£83.27m
Autres dépenses	UK£68.27m
Les revenus	UK£15.00m

Derniers bénéfices déclarés

Jun 30, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	0.29
Marge brute	54.75%
Marge bénéficiaire nette	9.86%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de ERGO?

Voir les performances historiques et les comparaisons

ERGO Aperçu des actions

Récompenses

Analyse des risques

Ergomed plc Concurrents

AIM:HVO

UK£172.8m

AIM:C4XD

UK£30.3m

LSE:GNS

UK£1.1b

AIM:BVXP

UK£195.7m

Historique des prix et performances

Nouvelles et mises à jour récentes

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Now 20% undervalued after recent price drop

Is It Time To Consider Buying Ergomed plc (LON:ERGO)?

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ergomed plc, Annual General Meeting, Jun 22, 2023

At UK£9.74, Is Ergomed plc (LON:ERGO) Worth Looking At Closely?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Ergomed plc (LON:ERGO) Shares Could Be 21% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Should You Be Adding Ergomed (LON:ERGO) To Your Watchlist Today?

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings: EPS misses analyst expectations

Ergomed plc, Annual General Meeting, Jun 10, 2022

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Less than half of directors are independent

Now 21% undervalued

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Full year 2021 earnings: EPS misses analyst expectations

Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Ergomed (LON:ERGO) Passed With Ease

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Calculating The Intrinsic Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Ergomed (LON:ERGO) Before It's Too Late

Getting In Cheap On Ergomed plc (LON:ERGO) Might Be Difficult

Ergomed plc (LON:ERGO) Shares Could Be 31% Above Their Intrinsic Value Estimate

Price target increased to UK£13.65

Non-Executive Director has left the company

Investor sentiment improved over the past week

Do Ergomed's (LON:ERGO) Earnings Warrant Your Attention?

Full year 2020 earnings released